Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: A new drug combination for cancer therapy

International Journal of Cancer

Volumn 128, Issue 3, 2011, Pages 691-701

  Biran, Anat ^a   Brownstein, Michael ^b   Haklai, Ronit ^a   Kloog, Yoel ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Aurora kinase; cancer; FTS; HDAC inhibitors; Ras; VPA

Indexed keywords

AURORA A KINASE; B RAF KINASE; FARNESYLTHIOSALICYLIC ACID; K RAS PROTEIN; RAS PROTEIN; SURVIVIN; VALPROIC ACID;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CELL DIVISION; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOWN-REGULATION; FARNESOL; FLOW CYTOMETRY; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LUNG NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; PROTEIN-SERINE-THREONINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SALICYLIC ACIDS; VALPROIC ACID;

EID: 78649893706     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25367     Document Type: Article

References (55)

1. Mottet D, Castronovo V,. Histone deacetylases: target enzymes for cancer therapy. Clin Exp Metastasis 2008; 25: 183-9.
2. Santini V, Gozzini A, Ferrari G,. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 2007; 8: 383-93.
3. Marks PA, Dokmanovic M,. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005; 14: 1497-511.
4. Moradei O, Vaisburg A, Martell RE,. Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents. Curr Top Med Chem 2008; 8: 841-58.
5. Shankar S, Srivastava RK,. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008; 615: 261-98.
6. Xu WS, Parmigiani RB, Marks PA,. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-52.
7. Michaelis M, Doerr HW, Cinatl J, Jr,. Valproic acid as anti-cancer drug. Curr Pharm Des 2007; 13: 3378-93.
8. Blaheta RA, Cinatl J, Jr,. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002; 22: 492-511.
9. Kuendgen A, Gattermann N,. Valproic acid for the treatment of myeloid malignancies. Cancer 2007; 110: 943-54.
10. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS,. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004; 64: 1079-86.
11. Kircher B, Schumacher P, Petzer A, Hoflehner E, Haun M, Nachbaur D, Gastl G,. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro. Eur J Haematol 2009; 83: 48-56.
12. Morotti A, Cilloni D, Messa F, Arruga F, Defilippi I, Carturan S, Catalano R, Rosso V, Chiarenza A, Pilatrino C, Guerrasio A, Taulli R, et al. Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells. Cancer 2006; 106: 1188-96.
13. Costello R, Bouabdallah R, Sainty D, Gastaut JA, Gabert J,. [Chronic myeloid leukemia, biological aspects]. Rev Med Interne 1996; 17: 213-23.
14. Quintas-Cardama A, Cortes J,. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009; 113: 1619-30.
15. Blum R, Kloog Y,. Tailoring Ras-pathway-inhibitor combinations for cancer therapy. Drug Resist Updat 2005; 8: 369-80.
16. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-84.
17. Saxena N, Lahiri SS, Hambarde S, Tripathi RP,. RAS: target for cancer therapy. Cancer Invest 2008; 26: 948-55.
18. Blum R, Cox AD, Kloog Y,. Inhibitors of chronically active ras: potential for treatment of human malignancies. Recent Pat Anticancer Drug Discov 2008; 3: 31-47.
19. Kloog Y, Cox AD,. RAS inhibitors: potential for cancer therapeutics. Mol Med Today 2000; 6: 398-402.
20. Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y,. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res 2002; 8: 555-65.
21. Weisz B, Giehl K, Gana-Weisz M, Egozi Y, Ben-Baruch G, Marciano D, Gierschik P, Kloog Y,. A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene 1999; 18: 2579-88.
22. Erlich S, Tal-Or P, Liebling R, Blum R, Karunagaran D, Kloog Y, Pinkas-Kramarski R,. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol 2006; 72: 427-36.
23. Haklai R, Elad-Sfadia G, Egozi Y, Kloog Y,. Orally administered FTS (Salirasib) inhibits human pancreatic tumor growth in nude mice. Cancer Chemother Pharmacol 2007; 61: 89-96.
24. Zundelevich A, Elad-Sfadia G, Haklai R, Kloog Y,. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid). Mol Cancer Ther 2007; 31: 31.
25. Shalom-Feuerstein R, Lindenboim L, Stein R, Cox AD, Kloog Y,. Restoration of sensitivity to anoikis in Ras-transformed rat intestinal epithelial cells by a Ras inhibitor. Cell Death Differ 2004; 11: 244-7.
26. Wang WD, Xu XM, Chen Y, Jiang P, Dong CZ, Wang Q,. Apoptosis of human Burkitt's lymphoma cells induced by 2-N,N-diethylaminocarbonyloxymethyl-1- diphenylmethyl-4-(3,4,5-trimethoxybe nzoyl) piperazine hydrochloride (PMS-1077). Arch Pharm Res 2009; 32: 1727-36.
27. Lu MC, Yang SH, Hwang SL, Lu YJ, Lin YH, Wang SR, Wu YC, Lin SR,. Induction of G2/M phase arrest by squamocin in chronic myeloid leukemia (K562) cells. Life Sci 2006; 78: 2378-83.
28. Lukasiewicz KB, Lingle WL,. Aurora A, centrosome structure, and the centrosome cycle. Environ Mol Mutagen 2009; 50: 602-19.
29. Blum R, Jacob-Hirsch J, Rechavi G, Kloog Y,. Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis. Mol Cancer Ther 2006; 5: 2337-47.
30. Wolanin K, Piwocka K,. [Role of survivin in mitosis]. Postepy Biochem 2007; 53: 10-8.
31. Delacour-Larose M, Hoang TM, Molla A,. [Survivin, the starlet of the passenger-protein complex: check-up for its tenth anniversary]. Med Sci (Paris) 2008; 24: 828-32.
32. Ruchaud S, Carmena M, Earnshaw WC,. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol 2007; 8: 798-812.
33. Vagnarelli P, Earnshaw WC,. Chromosomal passengers: the four-dimensional regulation of mitotic events. Chromosoma 2004; 113: 211-22.
34. Zhang XH, Rao M, Loprieato JA, Hong JA, Zhao M, Chen GZ, Humphries AE, Nguyen DM, Trepel JB, Yu X, Schrump DS,. Aurora A. Aurora. B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther 2008; 7: 1388-97.
35. Vader G, Lens SM,. The Aurora kinase family in cell division and cancer. Biochim Biophys Acta 2008; 1786: 60-72.
36. Blum R, Elkon R, Yaari S, Zundelevich A, Jacob-Hirsch J, Rechavi G, Shamir R, Kloog Y,. Gene expression signature of human cancer cell lines treated with the Ras inhibitor Salirasib (S-farnesylthiosalicylic acid). Cancer Res 2007; 67: 3320-8.
37. Shannon KB, Salmon ED, Chromosome dynamics: new light on Aurora B kinase function. Curr Biol 2002; 12: R458-60.
38. Vas AC, Clarke DJ,. Aurora B kinases restrict chromosome decondensation to telophase of mitosis. Cell Cycle 2008; 7: 293-6.
39. Terada Y,. Role of chromosomal passenger complex in chromosome segregation and cytokinesis. Cell Struct Funct 2001; 26: 653-7.
40. Kollareddy M, Dzubak P, Zheleva D, Hajduch M,. Aurora kinases: structure, functions and their association with cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008; 152: 27-33.
41. Fujiwara T, Harigae H, Okitsu Y, Takahashi S, Yokoyama H, Yamada MF, Ishizawa K, Kameoka J, Kaku M, Sasaki T,. Expression analyses and transcriptional regulation of mouse nucleolar spindle-associated protein gene in erythroid cells: essential role of NF-Y. Br J Haematol 2006; 135: 583-90.
42. Ribbeck K, Groen AC, Santarella R, Bohnsack MT, Raemaekers T, Kocher T, Gentzel M, Gorlich D, Wilm M, Carmeliet G, Mitchison TJ, Ellenberg J, et al. NuSAP, a mitotic RanGTP target that stabilizes and cross-links microtubules. Mol Biol Cell 2006; 17: 2646-60.
43. Ribbeck K, Raemaekers T, Carmeliet G, Mattaj IW,. A role for NuSAP in linking microtubules to mitotic chromosomes. Curr Biol 2007; 17: 230-6.
44. Raemaekers T, Ribbeck K, Beaudouin J, Annaert W, Van Camp M, Stockmans I, Smets N, Bouillon R, Ellenberg J, Carmeliet G,. NuSAP, a novel microtubule-associated protein involved in mitotic spindle organization. J Cell Biol 2003; 162: 1017-29.
45. Blum R, Nakdimon I, Goldberg L, Elkon R, Shamir R, Rechavi G, Kloog Y,. E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition. Int J Cancer 2006; 119: 527-38.
46. Hu Q, Lu JF, Luo R, Sen S, Maity SN,. Inhibition of CBF/NF-Y mediated transcription activation arrests cells at G2/M phase and suppresses expression of genes activated at G2/M phase of the cell cycle. Nucleic Acids Res 2006; 34: 6272-85.
47. Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK,. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005; 7: 646-57.
48. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 2004; 101: 540-5.
49. Nome RV, Bratland A, Harman G, Fodstad O, Andersson Y, Ree AH,. Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death. Mol Cancer Ther 2005; 4: 1231-8.
50. Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK,. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Int J Mol Med 2005; 16: 1125-38.
51. Hitomi T, Matsuzaki Y, Yokota T, Takaoka Y, Sakai T,. p15(INK4b) in HDAC inhibitor-induced growth arrest. FEBS Lett 2003; 554: 347-50.
52. Yokota T, Matsuzaki Y, Sakai T,. Trichostatin A activates p18INK4c gene: differential activation and cooperation with p19INK4d gene. FEBS Lett 2004; 574: 171-5.
53. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, Westbrook TF, Wong KK, Elledge SJ,. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 2009; 137: 835-48.
54. Macurek L, Lindqvist A, Lim D, Lampson MA, Klompmaker R, Freire R, Clouin C, Taylor SS, Yaffe MB, Medema RH,. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature 2008; 455: 119-23.
55. Seki A, Coppinger JA, Jang CY, Yates JR, Fang G,. Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 2008; 320: 1655-8.